Introducing the science behind targeted treatments and immunotherapies for NSCLC

Format: This is a live, in person event, with the option to attend virtually.

Description: In the morning Elaine focuses on the genetic faults that drive non-small cell lung cancer (NSCLC) and the targeted treatments that exploit them, such as inhibitors of EGFR, ALK, ROS1, B-Raf, HER2, RET, MET and K-RAS G12C. The afternoon is about NSCLC’s relationship with the immune system and the checkpoint inhibitor group of immunotherapies, which include PD-1, PD-L1 and CTLA-4
targeted antibodies.

Audience: This content is ideal for research nurses, clinical nurse specialists, pharmacists and clinical trials coordinators. It may also be of interest to other healthcare professionals involved in the diagnosis and treatment of people with lung cancer.

Cost: £150 (or £140 to attend virtually)

To book, contact:

View a PDF of the programme